CA2238710C - New amino alcohol derivatives, processes for their production and pharmaceutical agents containing these compounds - Google Patents
New amino alcohol derivatives, processes for their production and pharmaceutical agents containing these compounds Download PDFInfo
- Publication number
- CA2238710C CA2238710C CA002238710A CA2238710A CA2238710C CA 2238710 C CA2238710 C CA 2238710C CA 002238710 A CA002238710 A CA 002238710A CA 2238710 A CA2238710 A CA 2238710A CA 2238710 C CA2238710 C CA 2238710C
- Authority
- CA
- Canada
- Prior art keywords
- hydroxymethyl
- cis
- carbon atoms
- denotes
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 C*(C)CCCC(NC(C)(*)C*)=O Chemical compound C*(C)CCCC(NC(C)(*)C*)=O 0.000 description 1
Abstract
Compounds of formula I (See formula I) in which R1 denotes hydrogen or methyl R2 denotes lower straight-chained or branched alkyl with 1 to 10 carbon atoms R3 denotes hydrogen or lower alkyl n denotes 0 - 12 R4 denotes alkyl, alkenyl or alkinyl with 6 to 24 carbon atoms, processes for the production thereof as well as pharmaceutical agents containing these compounds for the treatment of osteoporosis.
Description
BOEHRINGER MANNHEIM GMBH
4273/00/kJG
New amino alcohol derivatives, processes for their production and pharmaceutical agents containing these compounds The present invention concerns new amino alcohol derivatives, processes for their production as well as pharmaceutical agents which contain these substances.
In healthy persons the anabolic and catabolic processes in the bone are almost in equilibrium i.e. the activity of the osteoblasts and osteoclasts is balanced. However, if this equilibrium is disturbed in favour of the osteoclasts and/or in favour of the osteoblasts the bone mass is reduced and there is a negative change in bone structure and function.
Inhibitors of bone resorption such as oestrogens, calcitonin and bisphosphonates have previously been used to treat disturbances of bone metabolism. However, the use of these substances is limited and also does not exhibit the desired effect in all cases. Compounds which have a stimulating effect on the formation of bone and in addition contribute to increasing an already reduced bone mass are therefore extremely important for the treatment of disturbances of bone metabolism. Substances with an osteoanabolic action for the therapy of osteoporosis were described in the European Patent Applications EP-A-625522 and EP-A-524023.
4273/00/kJG
New amino alcohol derivatives, processes for their production and pharmaceutical agents containing these compounds The present invention concerns new amino alcohol derivatives, processes for their production as well as pharmaceutical agents which contain these substances.
In healthy persons the anabolic and catabolic processes in the bone are almost in equilibrium i.e. the activity of the osteoblasts and osteoclasts is balanced. However, if this equilibrium is disturbed in favour of the osteoclasts and/or in favour of the osteoblasts the bone mass is reduced and there is a negative change in bone structure and function.
Inhibitors of bone resorption such as oestrogens, calcitonin and bisphosphonates have previously been used to treat disturbances of bone metabolism. However, the use of these substances is limited and also does not exhibit the desired effect in all cases. Compounds which have a stimulating effect on the formation of bone and in addition contribute to increasing an already reduced bone mass are therefore extremely important for the treatment of disturbances of bone metabolism. Substances with an osteoanabolic action for the therapy of osteoporosis were described in the European Patent Applications EP-A-625522 and EP-A-524023.
Surprisingly it was now found that amino alcohol derivatives of the present invention have a stimulating effect on the formation of bone and are therefore suitable for the broad treatment of disturbances of bone metabolism. They can be used particularly well for cases in which the formation of bone is disturbed i.e. they are suitable for the treatment of osteopenic diseases of the skeletal system such as e.g. osteoporosis including osteogenesis imperfecta but also to support bone regeneration and osteoinduction such as e.g. in orthopaedic and orthodontic indications, in the healing of fractures, osteosyntheses, pseudoarthroses and the settling of bone implants.
Based on these properties they can also be used in the prevention of osteoporosis.
As a result of their influence on bone metabolism they additionally form a basis for the treatment of rheumatoid arthritis, osteoarthritis and degenerative arthrosis.
The present invention concerns new compounds of the general formula (I) (I) R4- CH ~ OR3 ( 2) n in which R1 - hydrogen or methyl R2 - lower straight-chained or branched alkyl with 1 to carbon atoms R3 - hydrogen or lower alkyl n - 0 - 12 R4 - alkyl, alkenyl or alkinyl with 6 to 24 carbon atoms, wherein in the case that R4 denotes alkyl, -(CH2)n-R4 may not be an unbranched alkyl chain with 8, 10, 12, 14 or 16 carbon atoms and in the case that R2 denotes methyl or isobutyl, -(CH2)n-R4 may not be (all-cis-4,7,10,13)-octadecatetraene as well as pharmacologically acceptable salts and optical isomers thereof.
In EP-A-208961 amino alcohol derivatives of formula (I) are described in which R1 denotes hydrogen or methyl, R3 denotes hydrogen, R2 denotes methyl or isopropyl and in which -(CH2)n-R4 denotes an unbranched alkyl chain with 14 carbon atoms. In J. Med. Chem. 35, 2939-51 (1995) amino alcohol derivatives of formula (I) are described in which R1, R3 denote hydrogen, R2 denotes methyl or isobutyl and in which -(CH2)n-R4 denotes an unbranched alkyl chain with 14 carbon atoms. A compound of formula (I) is described in Biochem. J. 288, 167-73 (1992) in which R1, R3 denote hydrogen, R2 denotes isobutyl and in which -(CH2)n-R4 denotes an unbranched alkyl chain with 10 carbon atoms. In J. Lipid Res. 13 (1), 86-91 (1972) and in DE-A-3418525 compounds of formula (I) are described in which R1, R3 denote hydrogen, R2 denotes ethyl and in which -(CH2)n-R4 denotes an unbranched alkyl chain with 8, 10, 12, 14 and 16 carbon atoms. All compounds are described as intermediate products without information on a possible use as pharmaceutical agents. Compounds of formula (I) in which R1, R3 are hydrogen, R2 is methyl or isobutyl and in which -(CH2)n-R4 is (all-cis-4,7,10,13)-octadecatetraene have been described in Life Sci. 56 (23/24), 2041-8 (1995) as cannabinoid receptor ligands.
Therefore pharmaceutical agents are also a subject matter of the invention which contain compounds of formula I
(I) R4- CH ~ OR3 ( 2) n in which R1 - hydrogen or methyl R2 - lower straight-chained or branched alkyl with 1 to carbon atoms R3 - hydrogen or lower alkyl n - 0 - 12 R4 - alkyl, alkenyl or alkinyl with 6 to 24 carbon atoms as well as pharmacologically acceptable salts and optical isomers thereof.
Lower alkyl is intended in all cases to represent a straight-chained or branched C1-C6 alkyl group such as e.g. methyl, ethyl, propyl, isopropyl, butyl, isobutyl, pentyl or hexyl in particular methyl, ethyl, propyl and butyl.
Alkyl is intended in all cases to represent a straight-chained or branched C6 - Clg alkyl group such as e.g.
hexyl, isohexyl, 2,2-dimethylhexyl, 5-methylhexyl, heptyl, isoheptyl, 6-methylheptyl, octyl, isooctyl, nonyl, isononyl, decyl, isodecyl, undecyl, isoundecyl, dodecyl, isododecyl, tridecyl, isotridecyl, tetradecyl, isotetradecyl, pentadecyl, isopentadecyl, hexadecyl, heptadecyl, isoheptadecyl or octadecyl in particular heptyl, decyl and dodecyl.
Alkenyl denotes in all cases a monounsaturated or polyunsaturated, optionally substituted, residue with 6 - 20 carbon atoms such as e.g. O1-hexenyl, ~1-octenyl, O9-nonenyl, O1-decenyl, Olo-decenyl, 01.4-decadienyl, O1, 4, 7-decatrienyl, 01.4, 7, lo-hexadecatetraenyl, O1-dodecenyl, ~5-dodecenyl, X1,4-undecadienyl, 014-tetra-decenyl, in particular ~1-decenyl, 01~4-decadienyl, 01,4,7-decatrienyl in which the double bonds can be cis or trans and in the case of polyunsaturated compounds all combinations are possible.
Alkinyl denotes in all cases a monounsaturated or polyunsaturated optionally substituted, residue with 6 -20 carbon atoms such as e.g. O1-decinyl, O1-noninyl, 01,3_tetradecadiinyl, 01~3-hexadecadiinyl, 01~3-octa-decadiinyl, in particular O1-decinyl.
Compounds of the general formula (I) contain at least one asymmetric carbon atom and therefore optically active compounds of the general formula (I) are also a subject matter of the present application.
Compounds of the general formula (I) are obtained by known processes for the formation of carboxylic acid amides from the amino alcohols of the general formula (II) HzN R2 (II) in which Rl, R2 and R3 have the above-mentioned meanings and carboxylic acid derivatives of the general formula (III) , O X
4- ~ (III) R (CH2)n in which R4 and n have the meanings stated above and X
can be a hydroxy or an activation group whereby if X
denotes hydroxy, the carboxyl group can be activated by the carbodiimide process and if X denotes an activating group, mixed anhydrides come into consideration and especially with lower alkyl esters of carbonic acid such as ethyl or isobutyl esters or active esters in particular p-nitrophenyl, 2,4,5-trichlorophenyl, N-hydroxysuccinimide or 1-hydroxybenzotriazole esters, or by condensation with nitriles of the general formula (IV) R4-(CH2)n+1-CN (IV) in which R4 and n have the meanings stated above (cf.
Liebigs Ann. Chem. 986-96 (1979)).
Compounds of the general formula (II) are produced by known processes preferably by the reduction of amino acids or they are commercially available.
Compounds of the general formula (III) are produced by known processes from compounds of the general formula (V) R4-(CH2)n+1-COOH (V) in which R4 and n have the meanings stated above.
Compounds of the general formula (IV) are produced by known processes for the synthesis of nitriles or they are commercially available.
Compounds of the general formula (V) are produced by known processes for chain elongation or synthesis of carboxylic acids or they are commercially available.
g Pure enantiomers of the compounds of formula (I) can be obtained by using optically active amino alcohols which can be produced by known processes e.g. by classical racemate resolution via salt formation with optically active acids or by reduction of optically active amino acids.
Compounds of the formula (I) can be administered orally, enterally, parenterally, topically, nasally, pulmonary or rectally in a liquid, solid or aerosol form in all usual non-toxic pharmaceutically acceptable carrier materials, adjuvants and additives. The compounds of formula (I) can be also applied locally on/or in the bones (possibly in a surgical operation). In this connection the term parenterally encompasses subcutaneous, intravenous and intramuscular administration or infusions. Oral forms of application can be for example tablets, capsules, coated tablets, syrups, solutions, suspensions, emulsions, elixirs etc.
which can contain one or several additives from the following groups such as e.g. flavourings, sweeteners, dyes and preservatives. Oral forms of administration contain the active component together with non-toxic pharmaceutically acceptable carrier materials which are suitable for the production of tablets, capsules, coated tablets etc. such as e.g. calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; starch, mannitol, methylcellulose, talcum, highly dispersed silicic acids, higher molecular fatty acids (such as stearic acid), peanut oil, olive oil, paraffin, miglyol, gelatin, agar-agar, magnesium stearate, bee wax, cetyl alcohol, lecithin, glycerol, animal and vegetable fats, solid high molecular polymers (such as polyethylene glycols). Tablets, capsules, coated tablets etc. can be provided with an appropriate _ g _ coating such as e.g. glyceryl monostearate or glyceryl distearate to prevent undesired side-effects in the stomach or to increase the duration of action by a delayed absorption in the gastro-intestinal tract. As an injection medium sterile injectable aqueous or oily solutions or suspensions are preferably used which contain the usual additives such as stabilizers and solubilizers. Such additives can for example be water, isotonic saline solution, 1,3-butanediol, fatty acids (such as oleic acid), monoglycerides and diglycerides or miglyol. All suitable non-irritating additives can be used for the rectal application which are solid at normal temperatures and liquid at rectal temperature such as e.g. cacao butter and polyethylene glycol. For aerosol application the pharmaceutically common carrier media are used. Creams, tinctures, gels, solutions or suspensions etc. containing pharmaceutically common additives are used for external applications.
An application directly on/or in the bones (possibly in a surgical operation) can either be achieved in a solution or suspension or bound to a carrier advantageously by infusion or injection (preferably locally) Carrier-bound compounds of formula (I) can for example be administered as gels, pastes or as a coating on implants.
Biocompatible and preferably biodegradable materials are used as a carrier. The materials preferably themselves additionally induce wound healing or osteogenesis.
For the local application it is preferable to embed the compounds of formula (I) in polymeric gels or films, to immobilize them in this manner and to apply this preparation directly to the site on the bones to be treated. Such polymeric base gels or films are composed for example of glycerol, methylcellulose, hyaluronic acid, polyethylene oxides and/or polyoxamers. Collagen, gelatine and alginate are also suitable and described for example in WO 93/00050 and WO 93/20859. Further polymers are polylactic acid (PLA) and copolymers of lactic acid and glycollic acid (PLPG) (Hollinger et al., J. Biodem. Mater. Res. 17 71-82 (1983)) as well as the bone derivative "demineralized bone matrix" (DBM) (Guterman et al. Kollagen Rel. Res. 8 419-4319 (1988).
Polymers which are used for example to adsorb TGFf3 are also suitable and described in EP-A-0 616 814 and in EP-A-0 567 391 and synthetic bone matrices according to WO
91/18558.
Other suitable carriers for compounds of formula (I) are materials which are usually used in the implantation of bone substitutes or of other therapeutically active substances. Such carriers are based for example also on calcium sulfate, tricalcium phosphate, hydroxyapatite and polyanhydrides. Apart from these biodegradable carriers, carriers are also suitable which are not biodegradable but biocompatible. Such carriers are for example sintered hydroxylapatite, bioglass, aluminates or other ceramic materials (e. g. calcium aluminate phosphate). These materials are preferably used in combination with the biodegradable materials such as in particular polylactic acid, hydroxylapatite, collagen or tricalcium phosphate. Further non-degradable polymers are described for example in the US patent 4,164,560.
It is particularly preferable to use a carrier which continuously releases the compounds of formula (I) at the site of action. Slow release pellets from Lnnovative Research of America, Toledo, Ohio, USA are for example particularly suitable for this. Pellets are particularly preferably used which release the compounds of formula (I) over several days preferably up to 100 days at a daily dose of 1-l0 mg/kg per day.
The dosage can depend on various factors such as the mode of administration, species, age and/or individual state. The daily dose that has to be administered of the active substance is 0.01 mg to approximately 100 mg/kg body weight, preferably 0.1 to 10 mg/kg body weight and can be administered singly or divided into several doses.
Apart from the compounds mentioned in the examples and compounds derived by combining all meanings of the substituents stated in the claims the following amino alcohol derivatives are preferred within the sense of the present invention:
Preferred compounds (PC):
(1) [1-(Hydroxymethyl)-ethyl]-octanamide (2) [1-(Hydroxymethyl)-propyl]-octanamide (3) [1-(Hydroxymethyl)-pentyl]-octanamide (4) [1-(Hydroxymethyl)-ethyl]-7-methyloctanamide (5) [1-(Hydroxymethyl)-butyl]-7-methyloctanamide (6) [1-(Hydroxymethyl)-propyl]-7,7-dimethyloctanamide (7) [1-(Hydroxymethyl)-pentyl]-7,7-dimethyloctanamide (8) [1-(Hydroxymethyl)-ethyl]-nonanamide (9) [1-(Hydroxymethyl)-butyl]-nonanamide (10) [1-(Hydroxymethyl)-ethyl]-4-methylnonanamide (11) [1-(Hydroxymethyl)-propyl]-8-methylnonanamide (12) [1-(Hydroxymethyl)-ethyl]-decanamide (13) [1-(Hydroxymethyl)-butyl]-decanamide (14) [1-(Hydroxymethyl)-propyl]-undecanamide (15) [1-(Hydroxymethyl)-pentyl]-undecanamide (16] [1-(Hydroxymethyl)-ethyl]-10-methylundecanamide (17) [1-(Hydroxymethyl)-butyl]-10-methylundecanamide (18] [1-(Hydroxymethyl)-propyl]-dodecanamide (19) [1-(Hydroxymethyl)-pentyl]-dodecanamide (20] [1-(Hydroxymethyl)-pentyl]-11-methyldodecanamide.
Based on these properties they can also be used in the prevention of osteoporosis.
As a result of their influence on bone metabolism they additionally form a basis for the treatment of rheumatoid arthritis, osteoarthritis and degenerative arthrosis.
The present invention concerns new compounds of the general formula (I) (I) R4- CH ~ OR3 ( 2) n in which R1 - hydrogen or methyl R2 - lower straight-chained or branched alkyl with 1 to carbon atoms R3 - hydrogen or lower alkyl n - 0 - 12 R4 - alkyl, alkenyl or alkinyl with 6 to 24 carbon atoms, wherein in the case that R4 denotes alkyl, -(CH2)n-R4 may not be an unbranched alkyl chain with 8, 10, 12, 14 or 16 carbon atoms and in the case that R2 denotes methyl or isobutyl, -(CH2)n-R4 may not be (all-cis-4,7,10,13)-octadecatetraene as well as pharmacologically acceptable salts and optical isomers thereof.
In EP-A-208961 amino alcohol derivatives of formula (I) are described in which R1 denotes hydrogen or methyl, R3 denotes hydrogen, R2 denotes methyl or isopropyl and in which -(CH2)n-R4 denotes an unbranched alkyl chain with 14 carbon atoms. In J. Med. Chem. 35, 2939-51 (1995) amino alcohol derivatives of formula (I) are described in which R1, R3 denote hydrogen, R2 denotes methyl or isobutyl and in which -(CH2)n-R4 denotes an unbranched alkyl chain with 14 carbon atoms. A compound of formula (I) is described in Biochem. J. 288, 167-73 (1992) in which R1, R3 denote hydrogen, R2 denotes isobutyl and in which -(CH2)n-R4 denotes an unbranched alkyl chain with 10 carbon atoms. In J. Lipid Res. 13 (1), 86-91 (1972) and in DE-A-3418525 compounds of formula (I) are described in which R1, R3 denote hydrogen, R2 denotes ethyl and in which -(CH2)n-R4 denotes an unbranched alkyl chain with 8, 10, 12, 14 and 16 carbon atoms. All compounds are described as intermediate products without information on a possible use as pharmaceutical agents. Compounds of formula (I) in which R1, R3 are hydrogen, R2 is methyl or isobutyl and in which -(CH2)n-R4 is (all-cis-4,7,10,13)-octadecatetraene have been described in Life Sci. 56 (23/24), 2041-8 (1995) as cannabinoid receptor ligands.
Therefore pharmaceutical agents are also a subject matter of the invention which contain compounds of formula I
(I) R4- CH ~ OR3 ( 2) n in which R1 - hydrogen or methyl R2 - lower straight-chained or branched alkyl with 1 to carbon atoms R3 - hydrogen or lower alkyl n - 0 - 12 R4 - alkyl, alkenyl or alkinyl with 6 to 24 carbon atoms as well as pharmacologically acceptable salts and optical isomers thereof.
Lower alkyl is intended in all cases to represent a straight-chained or branched C1-C6 alkyl group such as e.g. methyl, ethyl, propyl, isopropyl, butyl, isobutyl, pentyl or hexyl in particular methyl, ethyl, propyl and butyl.
Alkyl is intended in all cases to represent a straight-chained or branched C6 - Clg alkyl group such as e.g.
hexyl, isohexyl, 2,2-dimethylhexyl, 5-methylhexyl, heptyl, isoheptyl, 6-methylheptyl, octyl, isooctyl, nonyl, isononyl, decyl, isodecyl, undecyl, isoundecyl, dodecyl, isododecyl, tridecyl, isotridecyl, tetradecyl, isotetradecyl, pentadecyl, isopentadecyl, hexadecyl, heptadecyl, isoheptadecyl or octadecyl in particular heptyl, decyl and dodecyl.
Alkenyl denotes in all cases a monounsaturated or polyunsaturated, optionally substituted, residue with 6 - 20 carbon atoms such as e.g. O1-hexenyl, ~1-octenyl, O9-nonenyl, O1-decenyl, Olo-decenyl, 01.4-decadienyl, O1, 4, 7-decatrienyl, 01.4, 7, lo-hexadecatetraenyl, O1-dodecenyl, ~5-dodecenyl, X1,4-undecadienyl, 014-tetra-decenyl, in particular ~1-decenyl, 01~4-decadienyl, 01,4,7-decatrienyl in which the double bonds can be cis or trans and in the case of polyunsaturated compounds all combinations are possible.
Alkinyl denotes in all cases a monounsaturated or polyunsaturated optionally substituted, residue with 6 -20 carbon atoms such as e.g. O1-decinyl, O1-noninyl, 01,3_tetradecadiinyl, 01~3-hexadecadiinyl, 01~3-octa-decadiinyl, in particular O1-decinyl.
Compounds of the general formula (I) contain at least one asymmetric carbon atom and therefore optically active compounds of the general formula (I) are also a subject matter of the present application.
Compounds of the general formula (I) are obtained by known processes for the formation of carboxylic acid amides from the amino alcohols of the general formula (II) HzN R2 (II) in which Rl, R2 and R3 have the above-mentioned meanings and carboxylic acid derivatives of the general formula (III) , O X
4- ~ (III) R (CH2)n in which R4 and n have the meanings stated above and X
can be a hydroxy or an activation group whereby if X
denotes hydroxy, the carboxyl group can be activated by the carbodiimide process and if X denotes an activating group, mixed anhydrides come into consideration and especially with lower alkyl esters of carbonic acid such as ethyl or isobutyl esters or active esters in particular p-nitrophenyl, 2,4,5-trichlorophenyl, N-hydroxysuccinimide or 1-hydroxybenzotriazole esters, or by condensation with nitriles of the general formula (IV) R4-(CH2)n+1-CN (IV) in which R4 and n have the meanings stated above (cf.
Liebigs Ann. Chem. 986-96 (1979)).
Compounds of the general formula (II) are produced by known processes preferably by the reduction of amino acids or they are commercially available.
Compounds of the general formula (III) are produced by known processes from compounds of the general formula (V) R4-(CH2)n+1-COOH (V) in which R4 and n have the meanings stated above.
Compounds of the general formula (IV) are produced by known processes for the synthesis of nitriles or they are commercially available.
Compounds of the general formula (V) are produced by known processes for chain elongation or synthesis of carboxylic acids or they are commercially available.
g Pure enantiomers of the compounds of formula (I) can be obtained by using optically active amino alcohols which can be produced by known processes e.g. by classical racemate resolution via salt formation with optically active acids or by reduction of optically active amino acids.
Compounds of the formula (I) can be administered orally, enterally, parenterally, topically, nasally, pulmonary or rectally in a liquid, solid or aerosol form in all usual non-toxic pharmaceutically acceptable carrier materials, adjuvants and additives. The compounds of formula (I) can be also applied locally on/or in the bones (possibly in a surgical operation). In this connection the term parenterally encompasses subcutaneous, intravenous and intramuscular administration or infusions. Oral forms of application can be for example tablets, capsules, coated tablets, syrups, solutions, suspensions, emulsions, elixirs etc.
which can contain one or several additives from the following groups such as e.g. flavourings, sweeteners, dyes and preservatives. Oral forms of administration contain the active component together with non-toxic pharmaceutically acceptable carrier materials which are suitable for the production of tablets, capsules, coated tablets etc. such as e.g. calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; starch, mannitol, methylcellulose, talcum, highly dispersed silicic acids, higher molecular fatty acids (such as stearic acid), peanut oil, olive oil, paraffin, miglyol, gelatin, agar-agar, magnesium stearate, bee wax, cetyl alcohol, lecithin, glycerol, animal and vegetable fats, solid high molecular polymers (such as polyethylene glycols). Tablets, capsules, coated tablets etc. can be provided with an appropriate _ g _ coating such as e.g. glyceryl monostearate or glyceryl distearate to prevent undesired side-effects in the stomach or to increase the duration of action by a delayed absorption in the gastro-intestinal tract. As an injection medium sterile injectable aqueous or oily solutions or suspensions are preferably used which contain the usual additives such as stabilizers and solubilizers. Such additives can for example be water, isotonic saline solution, 1,3-butanediol, fatty acids (such as oleic acid), monoglycerides and diglycerides or miglyol. All suitable non-irritating additives can be used for the rectal application which are solid at normal temperatures and liquid at rectal temperature such as e.g. cacao butter and polyethylene glycol. For aerosol application the pharmaceutically common carrier media are used. Creams, tinctures, gels, solutions or suspensions etc. containing pharmaceutically common additives are used for external applications.
An application directly on/or in the bones (possibly in a surgical operation) can either be achieved in a solution or suspension or bound to a carrier advantageously by infusion or injection (preferably locally) Carrier-bound compounds of formula (I) can for example be administered as gels, pastes or as a coating on implants.
Biocompatible and preferably biodegradable materials are used as a carrier. The materials preferably themselves additionally induce wound healing or osteogenesis.
For the local application it is preferable to embed the compounds of formula (I) in polymeric gels or films, to immobilize them in this manner and to apply this preparation directly to the site on the bones to be treated. Such polymeric base gels or films are composed for example of glycerol, methylcellulose, hyaluronic acid, polyethylene oxides and/or polyoxamers. Collagen, gelatine and alginate are also suitable and described for example in WO 93/00050 and WO 93/20859. Further polymers are polylactic acid (PLA) and copolymers of lactic acid and glycollic acid (PLPG) (Hollinger et al., J. Biodem. Mater. Res. 17 71-82 (1983)) as well as the bone derivative "demineralized bone matrix" (DBM) (Guterman et al. Kollagen Rel. Res. 8 419-4319 (1988).
Polymers which are used for example to adsorb TGFf3 are also suitable and described in EP-A-0 616 814 and in EP-A-0 567 391 and synthetic bone matrices according to WO
91/18558.
Other suitable carriers for compounds of formula (I) are materials which are usually used in the implantation of bone substitutes or of other therapeutically active substances. Such carriers are based for example also on calcium sulfate, tricalcium phosphate, hydroxyapatite and polyanhydrides. Apart from these biodegradable carriers, carriers are also suitable which are not biodegradable but biocompatible. Such carriers are for example sintered hydroxylapatite, bioglass, aluminates or other ceramic materials (e. g. calcium aluminate phosphate). These materials are preferably used in combination with the biodegradable materials such as in particular polylactic acid, hydroxylapatite, collagen or tricalcium phosphate. Further non-degradable polymers are described for example in the US patent 4,164,560.
It is particularly preferable to use a carrier which continuously releases the compounds of formula (I) at the site of action. Slow release pellets from Lnnovative Research of America, Toledo, Ohio, USA are for example particularly suitable for this. Pellets are particularly preferably used which release the compounds of formula (I) over several days preferably up to 100 days at a daily dose of 1-l0 mg/kg per day.
The dosage can depend on various factors such as the mode of administration, species, age and/or individual state. The daily dose that has to be administered of the active substance is 0.01 mg to approximately 100 mg/kg body weight, preferably 0.1 to 10 mg/kg body weight and can be administered singly or divided into several doses.
Apart from the compounds mentioned in the examples and compounds derived by combining all meanings of the substituents stated in the claims the following amino alcohol derivatives are preferred within the sense of the present invention:
Preferred compounds (PC):
(1) [1-(Hydroxymethyl)-ethyl]-octanamide (2) [1-(Hydroxymethyl)-propyl]-octanamide (3) [1-(Hydroxymethyl)-pentyl]-octanamide (4) [1-(Hydroxymethyl)-ethyl]-7-methyloctanamide (5) [1-(Hydroxymethyl)-butyl]-7-methyloctanamide (6) [1-(Hydroxymethyl)-propyl]-7,7-dimethyloctanamide (7) [1-(Hydroxymethyl)-pentyl]-7,7-dimethyloctanamide (8) [1-(Hydroxymethyl)-ethyl]-nonanamide (9) [1-(Hydroxymethyl)-butyl]-nonanamide (10) [1-(Hydroxymethyl)-ethyl]-4-methylnonanamide (11) [1-(Hydroxymethyl)-propyl]-8-methylnonanamide (12) [1-(Hydroxymethyl)-ethyl]-decanamide (13) [1-(Hydroxymethyl)-butyl]-decanamide (14) [1-(Hydroxymethyl)-propyl]-undecanamide (15) [1-(Hydroxymethyl)-pentyl]-undecanamide (16] [1-(Hydroxymethyl)-ethyl]-10-methylundecanamide (17) [1-(Hydroxymethyl)-butyl]-10-methylundecanamide (18] [1-(Hydroxymethyl)-propyl]-dodecanamide (19) [1-(Hydroxymethyl)-pentyl]-dodecanamide (20] [1-(Hydroxymethyl)-pentyl]-11-methyldodecanamide.
(21) [1-(Hydroxymethyl)-butyl]-11-methyldodecanamide (22] [1-(Hydroxymethyl)-pentyl]-tridecanamide (23) [1-(Hydroxymethyl)-pentyl]-12-methyltridecanamide (24] [1-(Hydroxymethyl)-ethyl]-tetradecanamide (25) [1-(Hydroxymethyl)-pentyl]-tetradecanamide (26] [1-(Hydroxymethyl)-butyl]-13-methyltetradecanamide (27) [1-(Hydroxymethyl)-pentyl]-13-methyltetra-decanamide (28] [1-(Hydroxymethyl)-ethyl]-pentadecanamide (29) [1-(Hydroxymethyl)-propyl]-pentadecanamide (30] [1-(Hydroxymethyl)-butyl]-pentadecanamide (31) [1-(Hydroxymethyl)-butyl]-14-methylpentadecanamide (32] [1-(Hydroxymethyl)-pentyl]-14-methylpenta-decanamide (33) [1-(Hydroxymethyl)-ethyl]-hexadecanamide (34] [1-(Hydroxymethyl)-ethyl]-15-methylhexadecanamide (35) [1-(Hydroxymethyl)-propyl]-15-methylhexadecanamide (36] [1-(Hydroxymethyl)-pentyl]-15-methylhexadecanamide (37) [1-(Hydroxymethyl)-ethyl]-heptadecanamide (38] [1-(Hydroxymethyl)-pentyl]-heptadecanamide (39) [1-(Hydroxymethyl)-propyl]-16-methylhepta decanamide (40] [1-(Hydroxymethyl)-pentyl]-16-methylhepta-decanamide (41) [1-(Hydroxymethyl)-pentyl]-octadecanamide (42] [1-(Hydroxymethyl)-butyl]-17-methyloctadecanamide (43) [1-(Hydroxymethyl)-pentyl]-17-methyloctadecanamide (44] [1-(Hydroxymethyl)-ethyl]-nonadecanamide (45) [1-(Hydroxymethyl)-pentyl]-nonadecanamide (46] [1-(Hydroxymethyl)-ethyl]-18-methylnonadecanamide (47) [1-(Hydroxymethyl)-ethyl]-eicosanamide (48] [1-(Hydroxymethyl)-butyl]-eicosanamide (49) [1-(Hydroxymethyl)-butyl]-19-methyleicosanamide (50] [1-(Hydroxymethyl)-ethyl]-heneicosanamide (51) [1-(Hydroxymethyl)-propyl]-docosanamide (52) [1-(Hydroxymethyl)-pentyl]-tricosanamide (53) [1-(Hydroxymethyl)-pentyl]-tetracosanamide (54) [1-(Hydroxymethyl)-butyl]-heptacosanamide (55) [1-(Hydroxymethyl)-pentyl]-heptacosanamide (56) [1-(Hydroxymethyl)-pentyl]-hexacosanamide (57) [1-(Hydroxymethyl)-ethyl]-heptacosanamide (58) [1-(Hydroxymethyl)-propyl]-octacosanamide (59) [1-(Hydroxymethyl)-butyl]-triacontanamide (60) [1-(Hydroxymethyl)-pentyl]-heptenamide (61) [1-(Hydroxymethyl)-ethyl]-trans-9-hexadecenamide (62) [1-(Hydroxymethyl)-propyl]-trans-9-hexadecenamide (63) [1-(Hydroxymethyl)-pentyl]-trans-9-hexadecenamide (64) [1-(Hydroxymethyl)-propyl]-(all-cis-11,14,17)-eicosatrienamide (65) [1-(Hydroxymethyl)-butyl]-(all-cis-11,14,17)-eicosatrienamide (66) [1-(Hydroxymethyl)-pentyl]-(all-cis-11,14,17)-eicosatrienamide (67) [1-(Hydroxymethyl)-propyl]-cis-10-heptadecenamide (68) [1-(Hydroxymethyl)-pentyl]-cis-10-heptadecenamide (69) [1-(Hydroxymethyl)-pentyl]-cis-10-nonadecenamide (70) [1-(Hydroxymethyl)-ethyl]-cis-3,cis-6-nona-dienamide (71) [1-(Hydroxymethyl)-butyl]-cis-3,cis-6-nona-dienamide (72) [1-(Hydroxymethyl)-ethyl]-cis-10-pentadecenamide (73) [1-(Hydroxymethyl)-pentyl]-cis-10-pentadecenamide (74) [1-(Hydroxymethyl)-butyl]-cis-12-octadecenamide (75) [1-(Hydroxymethyl)-propyl]-cis-13-octadecenamide (76) [1-(Hydroxymethyl)-pentyl]-cis-13-octadecenamide (77) [1-(Hydroxymethyl)-ethyl]-cis-7-octadecenamide (78) [1-(Hydroxymethyl)-ethyl]-cis-8-eicosenamide (79) [1-(Hydroxymethyl)-butyl]-cis-8-eicosenamide (80) [1-(Hydroxymethyl)-ethyl]-traps-9-tetradecenamide (81) [1-(Hydroxymethyl)-propyl]-traps-9-tetradecenamide (82) [1-(Hydroxymethyl)-pentyl]-traps-9-tetradecenamide (83) [1-(Hydroxymethyl)-pentyl]-cis-9,cis-11-octadeca-dienamide (84) [1-(Hydroxymethyl)-ethyl]-cis-9,cis-12-octadeca-dienamide (85) [1-(Hydroxymethyl)-butyl]-cis-9,cis-12-octadeca-dienamide (86) [1-(Hydroxymethyl)-propyl]-traps-9-octadecenamide (87) [1-(Hydroxymethyl)-butyl]-traps-9-octadecenamide (88) [1-(Hydroxymethyl)-ethyl]-cis-9-octadecenamide (89) [1-(Hydroxymethyl)-propyl]-cis-9-octadecenamide (90) [1-(Hydroxymethyl)-ethyl]-(all-traps-9,11,13,15)-octadecatetraenamide (91) [1-(Hydroxymethyl)-pentyl]-(all-traps-9,11,13,15)-octadecatetraenamide (92) [1-(Hydroxymethyl)-butyl]-(all-cis-9,11,13,15)-octadecatetraenamide (93) [1-(Hydroxymethyl)-pentyl]-(all-cis-9,11,13,15)-octadecatetraenamide (94) [1-(Hydroxymethyl)-ethyl]-cis-11-octadecenamide (95) [1-(Hydroxymethyl)-pentyl]-cis-11-octadecenamide (96) [1-(Hydroxymethyl)-ethyl]-cis-13-docosenamide (97) [1-(Hydroxymethyl)-propyl]-(all-cis-13,16,19)-docosatrienamide (98) [1-(Hydroxymethyl)-pentyl]-(all-cis-13,16,19)-docosatrienamide (99) [1-(Hydroxymethyl)-ethyl]-(all-cis-9,12,15)-octadecatrienamide (100) [1-(Hydroxymethyl)-ethyl]-(all-cis-8,11,14)-eicosatrienamide (101) [1-(Hydroxymethyl)-propyl]-(all-cis-8,11,14)-eicosatrienamide (102) [1-(Hydroxymethyl)-butyl]-(all-cis-8,11,14)-eicosatrienamide (103) [1-(Hydroxymethyl)-pentyl]-(all-cis-8,11,14)-eicosatrienamide (104) [1-(Hydroxymethyl)-ethyl]-trans-11-octadecenamide (105) [1-(Hydroxymethyl)-pentyl)-trans-13-docosenamide (106) [1-(Hydroxymethyl)-propyl]-traps-9,trans-12-octadecadienamide (107) [1-(Hydroxymethyl)-ethyl]-cis-9-tetradecenamide (108) [1-(Hydroxymethyl)-propyl]-cis-9-tetradecenamide (109) [1-(Hydroxymethyl)-butyl]-cis-9-tetradecenamide (110) [1-(Hydroxymethyl)-ethyl]-cis-9-hexadecenamide (111) [1-(Hydroxymethyl)-methylbutyl]-cis-9-hexa-decenamide (112) [1-(Hydroxymethyl)-butyl]-cis-9-hexadecenamide (113) [1-(Hydroxymethyl)-ethyl]-10-undecenamide (114) [1-(Hydroxymethyl)-pentyl]-(all-cis-8,11,14)-eicosatrienamide (115) [1-(Hydroxymethyl)-pentyl]-cis-ll,cis-14-eicosadienamide (116) [1-(Hydroxymethyl)-ethyl]-cis-11-eicosenamide (117) [1-(Hydroxymethyl)-pentyl]-cis-~11-eicosenamide (118) [1-(Hydroxymethyl)-ethyl)-cis-15-tetracosenamide (119) [1-(Hydroxymethyl)-propyl]-cis-15-tetracosenamide (120) [1-(Hydroxymethyl)-pentyl]-11-dodecenamide (121) [1-(Hydroxymethyl)-ethyl]-9-decenamide (122) [1-(Hydroxymethyl)-butyl]-16-heptadecenamide (123) [1-(Hydroxymethyl)-ethyl]-(all-cis-11,14,17)-eicosatrienamide (124) [1-(Hydroxymethyl)-butyl)-(all-cis-11,14,17)-eicosatrienamide (125) [1-(Hydroxymethyl)-pentyl]-(all-cis-11,14,17)-eicosatrienamide (126) [1-(Hydroxymethyl)-methylbutyl]-cis-13-eicosenamide (127) [1-(Hydroxymethyl)-ethyl]-cis-l3,cis-13-docosadienamide (128) [1-(Hydroxymethyl)-propyl]-(all-cis-7,10,13,16)-docosatetraenamide (129) [1-(Hydroxymethyl)-ethyl]-22-tricosenamide (130) [1-(Hydroxymethyl)-ethyl]-9-tetradecynamide (131) [1-(Hydroxymethyl)-butyl]-9-tetradecynamide (132) [1-(Hydroxymethyl)-ethyl]-13-eicosynamide (133) [1-(Hydroxymethyl)-ethyl]-10,12-nonacosadiinamide (134) [1-(Hydroxymethyl)-ethyl]-10,12-octadecadiinamide (135) [1-(Hydroxymethyl)-pentyl]-10,12-octadecadiinamide (136) [1-(Hydroxymethyl)-butyl]-9-octadecynamide (137) [1-(Hydroxymethyl)-propyl]-9-octadecynamide (138) [1-(Hydroxymethyl)-methylbutyl]-9-octadecynamide (139) [1-(Hydroxymethyl)-ethyl]-10-undecynamide (140) [1-(Hydroxymethyl)-butyl]-10,12-tricosadiynamide (141) [1-(Hydroxymethyl)-ethyl]-10,12-pentacosadiynamide (142) [1-(Hydroxymethyl)-ethyl]-10,12-heptacosadiynamide The following examples exhibit some of the process variants that can be used to synthesize the compounds according to the invention. However, they are not intended to limit the subject matter of the invention.
The structure of the compounds was ensured by 1H and optionally by 13C-NMR spectroscopy. The purity of the substances was determined by means of C, H, N elemental analysis as well as by thin layer chromatography.
General working instructions General working instruction A' 25 mmol carboxylic acid of formula III is dissolved in 125 ml THF. After addition of 30 mmol 1,1'-carbonyl-diimidazole it is boiled for 10 min under reflux.
50 mmol amino alcohol of formula II is added at room temperature. After a further 3 hours under reflux it is concentrated in a vacuum. The residue is taken up in diethyl ether, washed with water, 0.5 N NaOH and water.
The organic phase is dried over magnesium sulfate and concentrated in a vacuum.
General working instruction B~
A solution of 25 mmol chloroformic acid isobutyl ester dissolved in 25 ml absolute dichloromethane is added dropwise at -10°C to a solution of 25 mmol carboxylic acid of formula III and 25 mmol triethylamine in 100 ml absolute dichloromethane. After 15 min a solution of 30 mmol amino alcohol of formula II and 30 mmol triethylamine in 75 ml absolute dichloromethane is added dropwise. It is stirred for a further 30 min at -10°C
before it is slowly heated to room temperature. The reaction mixture is concentrated in a vacuum, taken up in diethyl ether and w4shed with water, 0.5 N NaOH and water. The organic phase is dried over magnesium sulfate and concentrated in a vacuum.
General working instruction C:
A solution of 25 mmol carboxylic acid chloride of formula III in 30 ml absolute dichloromethane is added dropwise at 10°C to a solution of 25 mmol amino alcohol of formula II and 25 mmol triethylamine in 100 absolute dichloromethane. After stirring for 48 hours at room temperature it is concentrated in a vacuum, the residue is taken up in diethyl ether and washed with water, 0.5 N HC1 and saturated NaCl. The organic phase is dried over magnesium sulfate and concentrated in a vacuum.
Examale 1 R-N-[1-(Hydroxymethyl)-propyl]-eicosanamide carboxylic acid: eicosanoic acid alcohol: R-2-amino-1-butanol It is prepared according to the general working instruction A. Yield 84 % colourless crystals; Fp 90-92°C
Example 2 R-N-[1-(Hydroxymethyl)-propyl]-(all-cis-9,12,15)-octadecatrienamide carboxylic acid: linolenic acid alcohol: R-2-amino-1-butanol It is prepared according to the general working instruction B. It was purified by chromatography on silica gel with ethyl acetate/isohexane (1:1). Yield 61 % colourless oil.
Example 3 N-[1-(Hydroxymethyl)-pentyl]-eicosanamide carboxylic acid: eicosanoic acid alcohol: 2-amino-1-hexanol It is prepared according to the general working instruction C: yield 65 % colourless crystals.
Example 4 N-[1-(Hydroxymethyl)-pentyl]-cis-3,cis-6-nonadienamide carboxylic acid: cis-3,cis-6-nonadienoic acid alcohol: 2-amino-1-hexanol It is prepared according to the general working instruction B. It was purified by chromatography on silica gel with ethyl acetate/isohexane (1:1). Yield 35 % colourless oil.
Example 5 N-[1-(Hydroxymethyl)-pentyl]-nonanamide carboxylic acid: nonanoic acid alcohol: 2-amino-1-hexanol It is prepared according to the general working instruction A. Yield 95 % colourless oil.
Example 6 R-N-[1-(Hydroxymethyl)-3-methylbutyl]-(all-cis-9,12,15)-octadecatrienamide carboxylic acid: linolenic acid alcohol: R-2-amino-4-methyl-1-pentanol It is prepared according to the general working instruction B. It was purified by chromatography on silica gel with ethyl acetate/isohexane (1:1). Yield 94 % colourless oil.
Example 7 R-N-[1-(Hydroxymethyl)-butyl]-(all-cis-9,12,15)-octadecatrienamide carboxylic acid: linolenic acid alcohol: R-2-amino-1-pentanol It is prepared according to the general working instruction B. It was purified by chromatography on silica gel with ethyl acetate/isohexane (I:1). Yield 86 % colourless oil.
Example 8 R-N-[1-(Hydroxymethyl)-propyl]-cis-3,cis-6-nonadienamide carboxylic acid: cis-3,cis-6-nonadienoic acid alcohol: R-2-amino-1-butanol Synthesis of cis-3 cis-6-nonadienoic acid cis-3,cis-6-Nonadien-1-of (150 mmol) is dissolved in 140 ml acetone and admixed with a mixture of 14 g chromiumtrioxide in 42 ml water and 12.6 ml concentrated sulphuric acid.,After 6 h at room temperature it is diluted with 70 ml water and the mixture is extracted with diethyl ether. The combined organic phases are extracted with soda solution, the soda solution is acidified and extracted with dichloromethane. After drying over magnesium sulfate it is concentrated and a colourless oil is obtained. (yield: 54 %) It is prepared according to the general working instruction A. Yield 95 % colourless oil.
Examp 1 a 9 R-N-[1-Hydroxymethyl)-pentyl]-(all-cis-9,12,15)octadeca-trienamide carboxylic acid: linolenic acid alcohol: R-2-amino-1-hexanol It is prepared according to the general working instruction B. It was purified by chromatography on silica gel with ethyl acetate/isohexane (1:1). Yield 48 % colourless oil.
Example 10 R-N-[1-Hydroxymethyl)-pentyl]-cis-9,cis-12-octadeca-dienamide carboxylic acid: linoleic acid alcohol: R-2-amino-1-hexanol It is prepared according to the general working instruction C. It was purified by chromatography on silica gel with ethyl acetate/heptane (2:1). Yield 55 colourless oil.
Example 11 N-[1-Hydroxymethyl)-pentyl]-cis-9-hexadecenamide carboxylic acid: palmitoleinic acid alcohol: 2-amino-1-hexanol It is prepared according to the general working instruction C. It was purified by chromatography on silica gel with ethyl acetate/heptane (1:1). Yield 75 colourless oil.
Example 12 S-N-[1-Hydroxymethyl)-pentyl]-cis-9-octadecenamide carboxylic acid: oleic acid alcohol: S-2-amino-1-hexanol It is prepared according to the general working instruction C. It was purified by chromatography on silica gel with ethyl acetate/heptane (2:1). Yield 40 colourless amorphous powder.
Example 13 8-N-[1-Hydroxymethyl)-pentyl]-9-octadecynamide carboxylic acid: octadecynoic acid alcohol: S-2-amino-1-hexanol It is prepared according to the general working instruction C. It was purified by chromatography on silica gel with ethyl acetate/heptane (2:1). Yield 51 colourless crystals.
Example 14 R-N-[1-hydroxymethyl)-pentyl]-cis-9-octadecenamide carboxylic acid: oleic acid alcohol: R-2-amino-1-hexanol It is prepared according to the general working instruction C. It was purified by chromatography on silica gel with ethyl acetate/heptane (2:1). Yield 65 colourless crystals.
Example 15 S-N-[1-Hydroxymethyl)-pentyl]-trans-9-octadecenamide carboxylic acid: elaidic acid alcohol: S-2-amino-1-hexanol It is prepared according to the general working instruction C. It was purified by chromatography on silica gel with ethyl acetate/heptane (2:1). Yield 55 0 colourless crystals.
Example 16 R-N-[1-Hydroxymethyl)-pentyl]-9-octadecynamide carboxylic acid: octadecynoic acid alcohol: R-2-amino-1-hexanol It is prepared according to the general working instruction C. It was purified by chromatography on silica gel with ethyl acetate/heptane (2:1). Yield 61 0 colourless crystals.
Example 17 R-N-[1-Hydroxymethyl)-pentyl]-trans-9-octadecenamide carboxylic acid: elaidic acid alcohol: R-2-amino-1-hexanol It is prepared according to the general working instruction C. It was purified by chromatography on silica gel with ethyl acetate/heptane (2:1). Yield 54 0 colourless amorphous powder.
Example 18 R-N-[1-Hydroxymethyl)-pentyl]-eicosanamide carboxylic acid: eicosanoic acid alcohol: R-2-amino-1-hexanol It is prepared according to the general working instruction C. It was purified by chromatography on silica gel with ethyl acetate/heptane (2:1). Yield 49 colourless crystals.
Example 19 N-[1-Hydroxymethyl)-pentyl]-cis-9-tetradecenamide carboxylic acid: myristeoleic acid alcohol: 2-amino-1-hexanol It is prepared according to the general working instruction C. It was purified by chromatography on silica gel with ethyl acetate/heptane (2:1). Yield 84 colourless oil.
Example 20 N-[1-Hydroxymethyl)-pentyl]-9-octadecynamide carboxylic acid: octadecynoic acid alcohol: 2-amino-1-hexanol It is prepared according to the general working instruction C. It was purified by chromatography on silica gel with ethyl acetate/heptane (1:1). Yield 65 colourless oil.
Example 21 N-[1-Hydroxymethyl)-pentyl]-trans-9-octadecenamide carboxylic acid: elaidic acid alcohol: 2-amino-1-hexanol It is prepared according to the general working instruction C. It was purified by chromatography on silica gel with ethyl acetate/heptane (1:1). Yield 80 colourless oil.
Example 22 N-[1-Hydroxymethyl)-pentyl]-9-tetradecynamide carboxylic acid: tetradecynoic acid alcohol: 2-amino-1-hexanol It is prepared according to the general working instruction C. It was purified by chromatography on silica gel with ethyl acetate/heptane (2:1). Yield 92 colourless oil.
Example 23 8-N-[1-Hydroxymethyl)-pentyl]-cis-9,cis-12-octadeca-dienamide carboxylic acid: linoleic acid alcohol: S-2-amino-1-hexanol It is prepared according to the general working instruction C. It was purified by chromatography on silica gel with ethyl acetate/heptane (2:1). Yield 47 colourless oil.
Example 24 N-[1-Hydroxymethyl)-pentyl]-cis-9,cis-12-octadeca-dienamide carboxylic acid: linoleic acid alcohol: 2-amino-1-hexanol It was prepared according to the general working instruction B. Yield 98 % colourless oil.
Example 25 N-[1-Hydroxymethyl)-pentyl]-6-heptenamide carboxylic acid: 6-heptenoic acid alcohol: 2-amino-1-hexanol It was prepared according to the general working instruction B. Yield 92 o colourless oil.
Example 26 N-[1-Hydroxymethyl)-pentyl]-cis-9-octadecenamide carboxylic acid: oleic acid alcohol: 2-amino-1-hexanol It was prepared according to the general working instruction A. Yield 78 % colourless oil.
Example 27 R-N-[1-Hydroxymethyl)-propyl]-cis-9,cis-12-octadeca-dienamide carboxylic acid: linoleic acid alcohol: R-2-amino-1-butanol It was prepared according to the general working instruction B. It was purified by chromatography on silica gel with ethyl acetate. Yield 54 o colourless oil.
Example 28 8-N-[1-Hydroxymethyl)-propyl]-cis-9,cis-12-octadeca-dienamide carboxylic acid: linoleic acid alcohol: S-2-amino-1-butanol It was prepared according to the general working instruction B. It was purified by chromatography on silica gel with ethyl acetate. Yield 48 % colourless oil.
Example 29 N-[1-Hydroxymethyl)-ethyl]-traps-9-octadecenamide carboxylic acid: elaidic acid alcohol: 2-amino-1-propanol It was prepared according to the general working instruction B. It was purified by chromatography on silica gel with ethyl acetate. Yield 72 % colourless oil.
Example 30 N-[1-Hydroxymethyl)-butyl]-cis-9-octadecenamide carboxylic acid: oleic acid alcohol: 2-amino-1-pentanol It is prepared according to the general working instruction C. It was purified by chromatography on silica gel with ethyl acetate/heptane (3:1). Yield 88 colourless oil.
Example 31 N-[1-Iiydroxymethyl)-ethyl]-9-octadecynamide carboxylic acid: octadecynoic acid alcohol: 2-amino-1-propanol It is prepared according to the general working instruction C. It was purified by chromatography on silica gel with ethyl acetate/heptane (1:1). Yield 68 colourless oil.
Example 32 Compounds of formula (I) were examined in a DNA
synthesis assay in primary cultures of osteoblasts from fetal rat calvariae. The experiments were carried out in accordance with Pfeilschifter et al., Endocrinology 126, 703 (1990).
Primary osteoblasts were isolated from foetal rat calvariae by sequential digestion with collagenase. In this process 5 cell fractions were obtained. A pool from the cell fractions 3-5 were cultured in vitro. The cells were cultured in an incubator at a relative air humidity of 95 %, a C02 content of 5 % and a temperature of 37°C.
The test substances were examined in the cultures of the first, second or third cell passage. For the examinations the cells were sown at a cell count of 7x103 cells (in 100 ~,1 culture medium) / well in microtitre plates at least 76 hours before applying the test substances. MEM Dulbecco (plus 4.5 g/1 glucose plus 3.7 g/1 NaHC03 without glutamine) was used as the culture medium to which 5 % foetal calf serum (FCS) and 5000 U/ml penicillin/streptomycin had been added.
Immediately before addition of the test substances to the cell culture the medium was replaced by 150 ~,1 medium which contained 1 mg/ml bovine serum albumin (BSA) instead of FCS. Test substances were added at the desired concentrations to the medium containing BSA.
TGFI31 (transforming growth factor !31) at concentrations of 0.1 - 0.2 ng/ml were also examined as a positive control. Three determinations were carried out per (positive) control or substance concentration. The cell cultures were incubated for 24 hours with test substances, a thymidine probe (1 ~,Ci methyl-3H-thymidine in 20 ~,1 PBS solution) being additionally present during the last 3 hours. At the end of the incubation period the cell cultures were washed three times with 0.9 saline solution and subsequently admixed with 100 ~,1 liquid scintillator each time (OptiPhase Supermix TM~).
Afterwards the radioactivity incorporated into the DNA
was measured in cpm in a liquid scintillation counter (1450 MicroBeta~). Cell cultures which had only received medium containing BSA served as controls (100 %).
Table I: Rate of DNA synthesis of primary osteoblastic cells of foetal rat calvariae in percent compared to the control (= 100 %) Compound Example 1 ~g/ml N-[1-hydroxymethyl)-pentyl]-(all- 9 367 cis-9,12,15)-octadecatrienamide N-[1-hydroxymethyl)-pentyl]-cis- 10 475 9,cis-12-octadecadienamide N-[1-hydroxymethyl)-pentyl]-cis-9- 11 191 hexadecenamide N-[1-hydroxymethyl)-pentyl]-cis-9- 19 298 tetradecenamide N-[1-hydroxymethyl)-pentyl]-9- 20 250 octadecynamide N-[1-hydroxymethyl)-pentyl]-trans- 21 188 9-octadecenamide N-[1-hydroxymethyl)-pentyl]-cis-9, 24 223 cis-12-octadecadienamide N-[1-hydroxymethyl)-pentyl]-cis-9- 26 296 octadecenamide N-[1-hydroxymethyl)-propyl]-cis-9, 27 252 cis-12-octadecadienamide
The structure of the compounds was ensured by 1H and optionally by 13C-NMR spectroscopy. The purity of the substances was determined by means of C, H, N elemental analysis as well as by thin layer chromatography.
General working instructions General working instruction A' 25 mmol carboxylic acid of formula III is dissolved in 125 ml THF. After addition of 30 mmol 1,1'-carbonyl-diimidazole it is boiled for 10 min under reflux.
50 mmol amino alcohol of formula II is added at room temperature. After a further 3 hours under reflux it is concentrated in a vacuum. The residue is taken up in diethyl ether, washed with water, 0.5 N NaOH and water.
The organic phase is dried over magnesium sulfate and concentrated in a vacuum.
General working instruction B~
A solution of 25 mmol chloroformic acid isobutyl ester dissolved in 25 ml absolute dichloromethane is added dropwise at -10°C to a solution of 25 mmol carboxylic acid of formula III and 25 mmol triethylamine in 100 ml absolute dichloromethane. After 15 min a solution of 30 mmol amino alcohol of formula II and 30 mmol triethylamine in 75 ml absolute dichloromethane is added dropwise. It is stirred for a further 30 min at -10°C
before it is slowly heated to room temperature. The reaction mixture is concentrated in a vacuum, taken up in diethyl ether and w4shed with water, 0.5 N NaOH and water. The organic phase is dried over magnesium sulfate and concentrated in a vacuum.
General working instruction C:
A solution of 25 mmol carboxylic acid chloride of formula III in 30 ml absolute dichloromethane is added dropwise at 10°C to a solution of 25 mmol amino alcohol of formula II and 25 mmol triethylamine in 100 absolute dichloromethane. After stirring for 48 hours at room temperature it is concentrated in a vacuum, the residue is taken up in diethyl ether and washed with water, 0.5 N HC1 and saturated NaCl. The organic phase is dried over magnesium sulfate and concentrated in a vacuum.
Examale 1 R-N-[1-(Hydroxymethyl)-propyl]-eicosanamide carboxylic acid: eicosanoic acid alcohol: R-2-amino-1-butanol It is prepared according to the general working instruction A. Yield 84 % colourless crystals; Fp 90-92°C
Example 2 R-N-[1-(Hydroxymethyl)-propyl]-(all-cis-9,12,15)-octadecatrienamide carboxylic acid: linolenic acid alcohol: R-2-amino-1-butanol It is prepared according to the general working instruction B. It was purified by chromatography on silica gel with ethyl acetate/isohexane (1:1). Yield 61 % colourless oil.
Example 3 N-[1-(Hydroxymethyl)-pentyl]-eicosanamide carboxylic acid: eicosanoic acid alcohol: 2-amino-1-hexanol It is prepared according to the general working instruction C: yield 65 % colourless crystals.
Example 4 N-[1-(Hydroxymethyl)-pentyl]-cis-3,cis-6-nonadienamide carboxylic acid: cis-3,cis-6-nonadienoic acid alcohol: 2-amino-1-hexanol It is prepared according to the general working instruction B. It was purified by chromatography on silica gel with ethyl acetate/isohexane (1:1). Yield 35 % colourless oil.
Example 5 N-[1-(Hydroxymethyl)-pentyl]-nonanamide carboxylic acid: nonanoic acid alcohol: 2-amino-1-hexanol It is prepared according to the general working instruction A. Yield 95 % colourless oil.
Example 6 R-N-[1-(Hydroxymethyl)-3-methylbutyl]-(all-cis-9,12,15)-octadecatrienamide carboxylic acid: linolenic acid alcohol: R-2-amino-4-methyl-1-pentanol It is prepared according to the general working instruction B. It was purified by chromatography on silica gel with ethyl acetate/isohexane (1:1). Yield 94 % colourless oil.
Example 7 R-N-[1-(Hydroxymethyl)-butyl]-(all-cis-9,12,15)-octadecatrienamide carboxylic acid: linolenic acid alcohol: R-2-amino-1-pentanol It is prepared according to the general working instruction B. It was purified by chromatography on silica gel with ethyl acetate/isohexane (I:1). Yield 86 % colourless oil.
Example 8 R-N-[1-(Hydroxymethyl)-propyl]-cis-3,cis-6-nonadienamide carboxylic acid: cis-3,cis-6-nonadienoic acid alcohol: R-2-amino-1-butanol Synthesis of cis-3 cis-6-nonadienoic acid cis-3,cis-6-Nonadien-1-of (150 mmol) is dissolved in 140 ml acetone and admixed with a mixture of 14 g chromiumtrioxide in 42 ml water and 12.6 ml concentrated sulphuric acid.,After 6 h at room temperature it is diluted with 70 ml water and the mixture is extracted with diethyl ether. The combined organic phases are extracted with soda solution, the soda solution is acidified and extracted with dichloromethane. After drying over magnesium sulfate it is concentrated and a colourless oil is obtained. (yield: 54 %) It is prepared according to the general working instruction A. Yield 95 % colourless oil.
Examp 1 a 9 R-N-[1-Hydroxymethyl)-pentyl]-(all-cis-9,12,15)octadeca-trienamide carboxylic acid: linolenic acid alcohol: R-2-amino-1-hexanol It is prepared according to the general working instruction B. It was purified by chromatography on silica gel with ethyl acetate/isohexane (1:1). Yield 48 % colourless oil.
Example 10 R-N-[1-Hydroxymethyl)-pentyl]-cis-9,cis-12-octadeca-dienamide carboxylic acid: linoleic acid alcohol: R-2-amino-1-hexanol It is prepared according to the general working instruction C. It was purified by chromatography on silica gel with ethyl acetate/heptane (2:1). Yield 55 colourless oil.
Example 11 N-[1-Hydroxymethyl)-pentyl]-cis-9-hexadecenamide carboxylic acid: palmitoleinic acid alcohol: 2-amino-1-hexanol It is prepared according to the general working instruction C. It was purified by chromatography on silica gel with ethyl acetate/heptane (1:1). Yield 75 colourless oil.
Example 12 S-N-[1-Hydroxymethyl)-pentyl]-cis-9-octadecenamide carboxylic acid: oleic acid alcohol: S-2-amino-1-hexanol It is prepared according to the general working instruction C. It was purified by chromatography on silica gel with ethyl acetate/heptane (2:1). Yield 40 colourless amorphous powder.
Example 13 8-N-[1-Hydroxymethyl)-pentyl]-9-octadecynamide carboxylic acid: octadecynoic acid alcohol: S-2-amino-1-hexanol It is prepared according to the general working instruction C. It was purified by chromatography on silica gel with ethyl acetate/heptane (2:1). Yield 51 colourless crystals.
Example 14 R-N-[1-hydroxymethyl)-pentyl]-cis-9-octadecenamide carboxylic acid: oleic acid alcohol: R-2-amino-1-hexanol It is prepared according to the general working instruction C. It was purified by chromatography on silica gel with ethyl acetate/heptane (2:1). Yield 65 colourless crystals.
Example 15 S-N-[1-Hydroxymethyl)-pentyl]-trans-9-octadecenamide carboxylic acid: elaidic acid alcohol: S-2-amino-1-hexanol It is prepared according to the general working instruction C. It was purified by chromatography on silica gel with ethyl acetate/heptane (2:1). Yield 55 0 colourless crystals.
Example 16 R-N-[1-Hydroxymethyl)-pentyl]-9-octadecynamide carboxylic acid: octadecynoic acid alcohol: R-2-amino-1-hexanol It is prepared according to the general working instruction C. It was purified by chromatography on silica gel with ethyl acetate/heptane (2:1). Yield 61 0 colourless crystals.
Example 17 R-N-[1-Hydroxymethyl)-pentyl]-trans-9-octadecenamide carboxylic acid: elaidic acid alcohol: R-2-amino-1-hexanol It is prepared according to the general working instruction C. It was purified by chromatography on silica gel with ethyl acetate/heptane (2:1). Yield 54 0 colourless amorphous powder.
Example 18 R-N-[1-Hydroxymethyl)-pentyl]-eicosanamide carboxylic acid: eicosanoic acid alcohol: R-2-amino-1-hexanol It is prepared according to the general working instruction C. It was purified by chromatography on silica gel with ethyl acetate/heptane (2:1). Yield 49 colourless crystals.
Example 19 N-[1-Hydroxymethyl)-pentyl]-cis-9-tetradecenamide carboxylic acid: myristeoleic acid alcohol: 2-amino-1-hexanol It is prepared according to the general working instruction C. It was purified by chromatography on silica gel with ethyl acetate/heptane (2:1). Yield 84 colourless oil.
Example 20 N-[1-Hydroxymethyl)-pentyl]-9-octadecynamide carboxylic acid: octadecynoic acid alcohol: 2-amino-1-hexanol It is prepared according to the general working instruction C. It was purified by chromatography on silica gel with ethyl acetate/heptane (1:1). Yield 65 colourless oil.
Example 21 N-[1-Hydroxymethyl)-pentyl]-trans-9-octadecenamide carboxylic acid: elaidic acid alcohol: 2-amino-1-hexanol It is prepared according to the general working instruction C. It was purified by chromatography on silica gel with ethyl acetate/heptane (1:1). Yield 80 colourless oil.
Example 22 N-[1-Hydroxymethyl)-pentyl]-9-tetradecynamide carboxylic acid: tetradecynoic acid alcohol: 2-amino-1-hexanol It is prepared according to the general working instruction C. It was purified by chromatography on silica gel with ethyl acetate/heptane (2:1). Yield 92 colourless oil.
Example 23 8-N-[1-Hydroxymethyl)-pentyl]-cis-9,cis-12-octadeca-dienamide carboxylic acid: linoleic acid alcohol: S-2-amino-1-hexanol It is prepared according to the general working instruction C. It was purified by chromatography on silica gel with ethyl acetate/heptane (2:1). Yield 47 colourless oil.
Example 24 N-[1-Hydroxymethyl)-pentyl]-cis-9,cis-12-octadeca-dienamide carboxylic acid: linoleic acid alcohol: 2-amino-1-hexanol It was prepared according to the general working instruction B. Yield 98 % colourless oil.
Example 25 N-[1-Hydroxymethyl)-pentyl]-6-heptenamide carboxylic acid: 6-heptenoic acid alcohol: 2-amino-1-hexanol It was prepared according to the general working instruction B. Yield 92 o colourless oil.
Example 26 N-[1-Hydroxymethyl)-pentyl]-cis-9-octadecenamide carboxylic acid: oleic acid alcohol: 2-amino-1-hexanol It was prepared according to the general working instruction A. Yield 78 % colourless oil.
Example 27 R-N-[1-Hydroxymethyl)-propyl]-cis-9,cis-12-octadeca-dienamide carboxylic acid: linoleic acid alcohol: R-2-amino-1-butanol It was prepared according to the general working instruction B. It was purified by chromatography on silica gel with ethyl acetate. Yield 54 o colourless oil.
Example 28 8-N-[1-Hydroxymethyl)-propyl]-cis-9,cis-12-octadeca-dienamide carboxylic acid: linoleic acid alcohol: S-2-amino-1-butanol It was prepared according to the general working instruction B. It was purified by chromatography on silica gel with ethyl acetate. Yield 48 % colourless oil.
Example 29 N-[1-Hydroxymethyl)-ethyl]-traps-9-octadecenamide carboxylic acid: elaidic acid alcohol: 2-amino-1-propanol It was prepared according to the general working instruction B. It was purified by chromatography on silica gel with ethyl acetate. Yield 72 % colourless oil.
Example 30 N-[1-Hydroxymethyl)-butyl]-cis-9-octadecenamide carboxylic acid: oleic acid alcohol: 2-amino-1-pentanol It is prepared according to the general working instruction C. It was purified by chromatography on silica gel with ethyl acetate/heptane (3:1). Yield 88 colourless oil.
Example 31 N-[1-Iiydroxymethyl)-ethyl]-9-octadecynamide carboxylic acid: octadecynoic acid alcohol: 2-amino-1-propanol It is prepared according to the general working instruction C. It was purified by chromatography on silica gel with ethyl acetate/heptane (1:1). Yield 68 colourless oil.
Example 32 Compounds of formula (I) were examined in a DNA
synthesis assay in primary cultures of osteoblasts from fetal rat calvariae. The experiments were carried out in accordance with Pfeilschifter et al., Endocrinology 126, 703 (1990).
Primary osteoblasts were isolated from foetal rat calvariae by sequential digestion with collagenase. In this process 5 cell fractions were obtained. A pool from the cell fractions 3-5 were cultured in vitro. The cells were cultured in an incubator at a relative air humidity of 95 %, a C02 content of 5 % and a temperature of 37°C.
The test substances were examined in the cultures of the first, second or third cell passage. For the examinations the cells were sown at a cell count of 7x103 cells (in 100 ~,1 culture medium) / well in microtitre plates at least 76 hours before applying the test substances. MEM Dulbecco (plus 4.5 g/1 glucose plus 3.7 g/1 NaHC03 without glutamine) was used as the culture medium to which 5 % foetal calf serum (FCS) and 5000 U/ml penicillin/streptomycin had been added.
Immediately before addition of the test substances to the cell culture the medium was replaced by 150 ~,1 medium which contained 1 mg/ml bovine serum albumin (BSA) instead of FCS. Test substances were added at the desired concentrations to the medium containing BSA.
TGFI31 (transforming growth factor !31) at concentrations of 0.1 - 0.2 ng/ml were also examined as a positive control. Three determinations were carried out per (positive) control or substance concentration. The cell cultures were incubated for 24 hours with test substances, a thymidine probe (1 ~,Ci methyl-3H-thymidine in 20 ~,1 PBS solution) being additionally present during the last 3 hours. At the end of the incubation period the cell cultures were washed three times with 0.9 saline solution and subsequently admixed with 100 ~,1 liquid scintillator each time (OptiPhase Supermix TM~).
Afterwards the radioactivity incorporated into the DNA
was measured in cpm in a liquid scintillation counter (1450 MicroBeta~). Cell cultures which had only received medium containing BSA served as controls (100 %).
Table I: Rate of DNA synthesis of primary osteoblastic cells of foetal rat calvariae in percent compared to the control (= 100 %) Compound Example 1 ~g/ml N-[1-hydroxymethyl)-pentyl]-(all- 9 367 cis-9,12,15)-octadecatrienamide N-[1-hydroxymethyl)-pentyl]-cis- 10 475 9,cis-12-octadecadienamide N-[1-hydroxymethyl)-pentyl]-cis-9- 11 191 hexadecenamide N-[1-hydroxymethyl)-pentyl]-cis-9- 19 298 tetradecenamide N-[1-hydroxymethyl)-pentyl]-9- 20 250 octadecynamide N-[1-hydroxymethyl)-pentyl]-trans- 21 188 9-octadecenamide N-[1-hydroxymethyl)-pentyl]-cis-9, 24 223 cis-12-octadecadienamide N-[1-hydroxymethyl)-pentyl]-cis-9- 26 296 octadecenamide N-[1-hydroxymethyl)-propyl]-cis-9, 27 252 cis-12-octadecadienamide
Claims (8)
1. A compound of formula I:
in which:
R1 is hydrogen or methyl;
R2 is a lower straight-chained or branched alkyl with 1 to 10 carbon atoms, with the proviso that:
when R2 is isopropyl, then -(CH2)n- R4 is not an unbranched chain with 6 or 10 carbon atoms, when R2 is methyl, then R1 is hydrogen, and (CH2)4 -R4 is not (all-cis-3, 6, 9, 12)-octadecatetranenyl, (all-cis-4,7,10,13)-octadecatetraene or an unbranched chain with 14 carbon atoms, and when R2 is isobutyl, then (CH2)4 -R4 is not (all-cis-4,7,10,13)-octadecatetraene;
R3 is hydrogen;
n is 0-12; and R4 is alkyl, alkenyl or alkynyl with 6 to 24 carbon atoms, with the proviso that when R4 is alkyl, -(CH2)4 -R4 is not an unbranched alkyl chain with 6, 8, 10, 12, 14 or 16 carbon atoms;
or a pharmacologically acceptable salt or optical isomer thereof.
in which:
R1 is hydrogen or methyl;
R2 is a lower straight-chained or branched alkyl with 1 to 10 carbon atoms, with the proviso that:
when R2 is isopropyl, then -(CH2)n- R4 is not an unbranched chain with 6 or 10 carbon atoms, when R2 is methyl, then R1 is hydrogen, and (CH2)4 -R4 is not (all-cis-3, 6, 9, 12)-octadecatetranenyl, (all-cis-4,7,10,13)-octadecatetraene or an unbranched chain with 14 carbon atoms, and when R2 is isobutyl, then (CH2)4 -R4 is not (all-cis-4,7,10,13)-octadecatetraene;
R3 is hydrogen;
n is 0-12; and R4 is alkyl, alkenyl or alkynyl with 6 to 24 carbon atoms, with the proviso that when R4 is alkyl, -(CH2)4 -R4 is not an unbranched alkyl chain with 6, 8, 10, 12, 14 or 16 carbon atoms;
or a pharmacologically acceptable salt or optical isomer thereof.
2. A process for the production of a compound of formula I:
or a pharmacologically acceptable salt or optical isomer thereof;
in which R1 denotes hydrogen or methyl;
R2 denotes lower straight-chained or branched alkyl with 1 to 10 carbon atoms, provided that:
when R2 denotes methyl or isobutyl, -(CH2)n -R4 is not (all-cis-4,7,10,13)-octadecatetraenyl or an unbranched chain with 14 carbon atoms;
R3 denotes hydrogen or lower alkyl;
n denotes 0-12; and R4 denotes alkyl, alkenyl or alkynyl with 6 to 24 carbon atoms, provided that:
when R4 denotes alkyl, -(CH2)n -R4 is not an unbranched alkyl chain with 8, 10, 12, 14 or 16 carbon atoms;
comprising reacting a compound of formula II:
in which R1, R2, and R3 are as defined above with:
(a) a compound of formula III:
in which R4 and n are as defined above and X represents an activating group;
or (b) a compound of formula IV:
R4 -(CH2)n+1 -CN (IV) in which R4 and n are as defined above; and, when desired, converting a compound (I) obtained into a different compound (I); or, converting a compound (I) obtained into a pharmacologically acceptable salt thereof; or converting a compound (I) obtained into an optical isomer thereof.
or a pharmacologically acceptable salt or optical isomer thereof;
in which R1 denotes hydrogen or methyl;
R2 denotes lower straight-chained or branched alkyl with 1 to 10 carbon atoms, provided that:
when R2 denotes methyl or isobutyl, -(CH2)n -R4 is not (all-cis-4,7,10,13)-octadecatetraenyl or an unbranched chain with 14 carbon atoms;
R3 denotes hydrogen or lower alkyl;
n denotes 0-12; and R4 denotes alkyl, alkenyl or alkynyl with 6 to 24 carbon atoms, provided that:
when R4 denotes alkyl, -(CH2)n -R4 is not an unbranched alkyl chain with 8, 10, 12, 14 or 16 carbon atoms;
comprising reacting a compound of formula II:
in which R1, R2, and R3 are as defined above with:
(a) a compound of formula III:
in which R4 and n are as defined above and X represents an activating group;
or (b) a compound of formula IV:
R4 -(CH2)n+1 -CN (IV) in which R4 and n are as defined above; and, when desired, converting a compound (I) obtained into a different compound (I); or, converting a compound (I) obtained into a pharmacologically acceptable salt thereof; or converting a compound (I) obtained into an optical isomer thereof.
3. A pharmaceutical composition comprising at least one compound of formula I:
or a pharmacologically acceptable salt or optical isomer thereof, in which:
R1 denotes hydrogen or methyl;
R2 denotes lower straight-chained or branched alkyl with 1 to 10 carbon atoms, with the proviso that:
when R2 is isopropyl, then -(CH2)n-R4 is not an unbranched chain with 6 or 10 carbon atoms, and when R2 is methyl, then R1 is hydrogen, and -(CH2)4 -R4 is not (all-cis-3, 6, 9, 12)-octadecatetranenyl, or an unbranched chain with 14 carbon atoms;
R3 denotes hydrogen;
n denotes 0-12; and R4 denotes alkyl, alkenyl or alkynyl with 6 to 24 carbon atoms, with the proviso that:
when R4 is alkyl, then -(CH2)4 -R4 is not an unbranched alkyl chain with 6, 8, 10, 12, 14 or 16 carbon atoms, in association with a pharmaceutically acceptable carrier.
or a pharmacologically acceptable salt or optical isomer thereof, in which:
R1 denotes hydrogen or methyl;
R2 denotes lower straight-chained or branched alkyl with 1 to 10 carbon atoms, with the proviso that:
when R2 is isopropyl, then -(CH2)n-R4 is not an unbranched chain with 6 or 10 carbon atoms, and when R2 is methyl, then R1 is hydrogen, and -(CH2)4 -R4 is not (all-cis-3, 6, 9, 12)-octadecatetranenyl, or an unbranched chain with 14 carbon atoms;
R3 denotes hydrogen;
n denotes 0-12; and R4 denotes alkyl, alkenyl or alkynyl with 6 to 24 carbon atoms, with the proviso that:
when R4 is alkyl, then -(CH2)4 -R4 is not an unbranched alkyl chain with 6, 8, 10, 12, 14 or 16 carbon atoms, in association with a pharmaceutically acceptable carrier.
4. Use of a compound of formula (I) as defined in claim 1 or 3, or a pharmacologically acceptable salt or optical isomer thereof, in the manufacture of a medicament for treating osteoporosis.
5. Use of a compound of formula (I) as defined in claim 1 or 3, or a pharmacologically acceptable salt or optical isomer thereof, in the manufacture of a medicament for treating a bone disease.
6. A compound of formula (I) as defined in claim 1 or 3, or a pharmacologically acceptable salt or optical isomer thereof, for use in treating a bone disease.
7. A compound of formula (I) as defined in claim 1 or 3, or a pharmacologically acceptable salt or optical isomer thereof, for use in treating osteoporosis.
8. A pharmaceutical composition for the treatment of osteopenic diseases, and for bone regeneration and osteoinduction, comprising a compound of formula (I), as defined in claim 1 or 3, or a pharmacologically acceptable salt or optical isomer thereof, in association with a pharmaceutically acceptable carrier.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19544635.6 | 1995-11-30 | ||
| DE19544635A DE19544635A1 (en) | 1995-11-30 | 1995-11-30 | Novel amino alcohol derivatives, processes for their preparation and medicaments containing these compounds |
| PCT/EP1996/005212 WO1997019909A1 (en) | 1995-11-30 | 1996-11-26 | Amino alcohol derivatives, methods of producing said derivatives and medicaments containing them |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2238710A1 CA2238710A1 (en) | 1997-06-05 |
| CA2238710C true CA2238710C (en) | 2006-04-18 |
Family
ID=36250918
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002238710A Expired - Fee Related CA2238710C (en) | 1995-11-30 | 1996-11-26 | New amino alcohol derivatives, processes for their production and pharmaceutical agents containing these compounds |
Country Status (1)
| Country | Link |
|---|---|
| CA (1) | CA2238710C (en) |
-
1996
- 1996-11-26 CA CA002238710A patent/CA2238710C/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CA2238710A1 (en) | 1997-06-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4757053A (en) | Pyridinecarboxamide or trimethoxybenzamide compounds derived from nitrogenous lipids, pharmaceutical compositions containing same which possess anti-convalsive and anti-epileptic properties | |
| US5300687A (en) | Trifluoromethylbenzylphosphonates useful in treating osteoporosis | |
| JPH07121895B2 (en) | Acyl-CoA: Saturated fatty acid amides as inhibitors of cholesterol acyltransferase | |
| EP0274453A2 (en) | Collagenase inhibitor derivatives, their preparation and pharmaceutical compositions containing them | |
| US4522759A (en) | Polyprenylcarboxylic acid amides | |
| EP0759026B1 (en) | Amide derivatives and their therapeutic use | |
| US4375477A (en) | Fluorinated methyl beta-alanine derivatives | |
| US6444832B1 (en) | Amino alcohol derivatives, method of producing said derivatives and medicaments containing them | |
| CA2238710C (en) | New amino alcohol derivatives, processes for their production and pharmaceutical agents containing these compounds | |
| JPH06312925A (en) | Cartilage-protection agent and new esculetin derivative | |
| EP1019062B1 (en) | Osteoblast-specific mitogens and drugs containing such compounds | |
| US5338858A (en) | Triazolyl, tetrazolyl and azido-substituted fatty acid analog enzyme substrates | |
| EP0712838B1 (en) | Acylphenylglycine derivative and preventive and remedy for diseases caused by increased collagenase activity containing said compound as active ingredient | |
| JPH05148277A (en) | Aminophosphonic acid derivative | |
| US6911553B1 (en) | Osteoblast-specific mitogens and drugs containing such compounds | |
| JPH06500777A (en) | Novel 17-β-estradiol derivatives, methods for their preparation, and medicaments containing these compounds | |
| US5010108A (en) | N-cycloalkylaminoethylbenzamide derivatives, their synthesis and pharmaceutical preparations | |
| MXPA00003006A (en) | Osteoblast-specific mitogens and drugs containing such compounds | |
| US4418205A (en) | 16-Amino-18,19,20-trinor-prostaglandin derivatives, and acid addition salts | |
| JP2001055327A (en) | New medicine containing hydroxamic acid derivative | |
| SU784231A1 (en) | Phenylcarbamoyl methyl ether -bromobenzoylthiopyruvic acid, showing analgesic activity | |
| JP2000086611A (en) | New metalloproteinase inhibitor | |
| JPH11322593A (en) | Anticancer agent and tubuline inhibitor containing acetamide derivative, and new acetamide derivative | |
| KR20040009047A (en) | Novel sphingosine-1-phosphate derivatives and preparation thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |